PCYOX1 Inhibitors

Chemical inhibitors of PCYOX1 operate primarily by curtailing the enzyme's access to its necessary substrates through various mechanisms. Allopurinol and its active metabolite, Oxypurinol, target xanthine oxidase, an upstream enzyme involved in purine degradation, which is essential for producing substrates that PCYOX1 utilizes. By inhibiting xanthine oxidase, these chemicals effectively reduce the concentration of metabolites available for PCYOX1, leading to its functional inhibition. Similarly, Febuxostat and Topiroxostat also inhibit xanthine oxidase, achieving a decrease in uric acid production, which is a substrate processed by PCYOX1. This action results in a decreased substrate pool for PCYOX1, leading to its functional inhibition. Tisopurine follows a comparable route, limiting xanthine oxidase activity and, consequently, the concentration of uric acid and related metabolites required for PCYOX1's enzymatic action, thus inhibiting its function. Pegloticase and Rasburicase exert their inhibitory effects on PCYOX1 by converting uric acid into allantoin, a compound outside the purine degradation pathway and not a substrate for PCYOX1. This enzymatic conversion leads to a depletion of the specific substrates that PCYOX1 needs, resulting in its functional inhibition. Benziodarone, too, inhibits PCYOX1 by blocking xanthine oxidase, leading to a diminished supply of uric acid and other metabolites that feed into the PCYOX1 pathway. Tiopronin, although it reduces levels of cystine, affects the metabolic pathway involving PCYOX1, indirectly inhibiting the enzyme's activity by reducing the availability of related substrates. Sulfinpyrazone and Probenecid inhibit uric acid reabsorption in the kidneys, thereby reducing systemic uric acid levels, which in turn diminishes the substrate availability for PCYOX1, leading to its functional inhibition. Lesinurad inhibits the uric acid transporter URAT1, reducing uric acid reabsorption, and thereby lowers plasma uric acid levels, leading to a functional inhibition of PCYOX1 by limiting its substrate access.